Sponsors
The bill aims to lower drug costs and standardize VA medication coverage through a codified national formulary and stronger contracting, but those gains come with risks of reduced local prescribing flexibility, higher costs for veterans needing non‑preferred drugs, and added administrative burdens while an advisory committee remains limited and nonbinding.
Veterans will likely pay less for many prescription drugs because the VA can negotiate additional discounts, preferred‑status agreements, and use blanket purchase/ordering volume to lower net prices.
Veterans will get more consistent, clinically informed access to VA‑covered medications because a codified national formulary and clinician input standardize coverage and reduce local variation in what drugs are available.
VA pharmacy management and oversight are likely to improve—codifying the formulary plus required reporting and evaluations increases predictability and transparency for Congress, the VA, and the public.
Veterans who need brand‑name or non‑formulary drugs could face higher out‑of‑pocket costs because the bill requires higher copayments for those drugs.
Veterans may lose access to some drugs if manufacturers refuse discounts or preferred‑status deals, or if the national formulary excludes certain brands—potentially restricting prescribing options.
Local VA facilities and clinicians could have reduced flexibility to prescribe non‑formulary or locally preferred drugs because a codified national formulary centralizes decisions.
Based on analysis of 4 sections of legislative text.
Codifies a VA national formulary, authorizes supplemental drug discounts and value‑based purchasing, mandates tiered copays favoring formulary generics, and creates a temporary advisory committee.
Introduced December 10, 2025 by Mariannette Miller-Meeks · Last progress December 10, 2025
Creates a codified VA national formulary and gives the Department of Veterans Affairs authority to negotiate supplemental discounts, formulary-preference agreements, and value-based purchasing arrangements for drugs and biologicals, while keeping existing statutory price limits. Requires VA to use best procurement practices, perform periodic outcome and budget reviews, and report results to congressional veterans committees. Establishes a tiered copayment schedule that makes 30-day generic or national-formulary drug copayments lower than 30-day brand-name or non-formulary copayments. Sets up a temporary Veterans Formulary Advisory Committee of up to ten members (including front-line VA clinicians or pharmacists) to provide nonbinding input on formulary changes; the committee must meet at least twice a year and terminates two years after creation. Overall, the bill focuses on strengthening VA drug purchasing tools, increasing oversight and reporting, adjusting copay incentives to favor formulary drugs, and creating a short-term advisory panel to give veterans and clinicians a voice in formulary decisions.